Summary
With the aim of assessing a new somatostatin analogue to prevent the metabolic changes induced by a 6-h nocturnal arrest of an insulin pump, nine C-peptide negative Type 1 (insulin-dependent) diabetic patients were submitted blindly to two interruptions (from 23.00 to 05.00 hours) of their continuous s.c. insulin infusion, once after a single s.c. injection at 23.00 hours of 50 μg SMS 201-995 (Sandostatin, Sandoz) and once after 0.9% NaCl. Plasma SMS 201-995 levels peaked at 24.00 hours and then declined with an elimination half-life averaging 144±15 min. Plasma glucagon and growth hormone levels were significantly reduced after SMS 201-995 whereas the progressive fall in plasma-free insulin levels from 23.00 to 05.00 hours was unaffected. In the control test, blood glucose levels tended to decrease slightly from 23.00 to 02.00 hours and then increased markedly from 02.00 to 05.00 hours (+5.3±1.5mmol/l) while after SMS 201-995 they decreased significantly from 23.00 to 02.00 hours (−2.6±0.5 mmol/l), resulting in values below 3 mmol/l in seven subjects, but showed a secondary increase until 05.00 hours (+3.5±1.5 mmol vs 23.00h; p<0.05 vs 0.9% NaCl). While the rises in plasma non-esterified fatty acid and glycerol levels were not reduced by SMS 201-995, the increase in plasma 3-hydroxybutyrate levels, although similar from 23.00 to 02.00 hours, was significantly reduced from 02.00 to 05.00 hours (+77±20 vs+124±31 μmol·l−1·h−1 p<0.005). Thus, SMS 201-995 significantly reduced the metabolic alterations due to a 6-h nocturnal interruption of a continuous s.c. insulin infusion but at the cost of a rather high risk of early hypoglycaemia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Pickup JC, Keen H, Viberti GC, White MC, Kohner EM, Parsons JA, Alberti KGMM (1980) Continuous subcutaneous insulin infusion in the treatment of diabetes mellitus. Diabetes Care 3: 290–300
Sonnenberg GE, Spraul M, Chantelau EA, Berger M (1985) Kontinuierliche subkutane Insulin-Infusionstherapie. Voraussetzungen, Indikationen und Risiken. Dtsch Med Wochenschr 110: 1859–1864
Bending JJ, Pickup JC, Keen H (1985) Frequency of diabetic ketoacidosis and hypoglycemic coma during treatment with continuous subcutaneous insulin infusion. Am J Med 79: 685–691
Kroc Collaborative Study Group (1984) Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicentre trial. N Engl J Med 311: 365–372
Mecklenburg R, Benson F, Benson J, Fredlund P, Guinn T, Metz R, Nielsen R, Sannar C (1984) Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA 252: 3265–3269
Peden NR, Braaten JT, McKendry JBR (1984) Diabetic ketoacidosis during long-term treatment with continuous subcutaneous insulin infusion. Diabetes Care 7: 1–5
Henrivaux P, Scheen AJ, Daubresse JC, Rinaldi AM, Lefèbvre PJ (1986) Incidence and severity of ketoacidosis due to technical problems during continuous subcutaneous insulin infusion. In: Proceedings of Cardiostim 86, Drug delivery systems and chronotherapy, Monaco, June, 1986
Scheen AJ, Henrivaux P, Jandrain B, Luyckx AS, Lefèbvre PJ (1985) Lack of systematic metabolic alterations after a one-hour interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients. Diabetes Care 8: 621–623
Scheen AJ, Castillo M, Jandrain B, Krzentowski G, Henrivaux P, Luyckx AS, Lefèbvre PJ (1984) Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion. Diabetes Care 7: 338–342
Krzentowski G, Scheen A, Castillo M, Luyckx AS, Lefèbvre PJ (1983) A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion. 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Diabetologia 24: 314–318
Scheen AJ, Henrivaux P, Jandrain B, Lefèbvre PJ (1986) Anti-insulin antibodies and metabolic deterioration after interruption of continuous subcutaneous insulin infusion. Diabetes Care 9: 673–674
Scheen AJ, Krzentowski G, Castillo M, Lefèbvre PJ, Luyckx AS (1983) A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion. 2. Marked attenuation of the metabolic deterioration by somatostatin. Diabetologia 24: 319–325
Bauer W, Briner U, Doepfner W, Haler R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 1133–1140
Pless J, Bauer W, Briner U, Doepfner W, Marbach P, Maurer R, Petcher TJ, Reubi JC, Vonderscher J (1986) Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroent 21 [Suppl 119]: 54–64
Kutz K, Nuesch E, Rosenthaler J (1986) Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroent 21 [Suppl 119]: 65–72
Spinas GA, Bock A, Keller U (1985) Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus. Diabetes Care 8: 429–435
Ewing DJ, Borsey DQ, Bellavere F, Clarke BF (1981) Cardiac autonomie neuropathy in diabetes: comparison of measures of R-R interval variation. Diabetologia 21: 18–24
Dole VP, Meinertz H (1960) Microdetermination of long chain fatty acids in plasma and tissues. J Biol Chem 235: 2595–2599
Williamson DH, Mellanby J (1974) D-(-)-3-hydroxybutyrate. In: Bergmeyer HU (ed) Methods of enzymatic analysis. Verlag Chemie, Weinheim. Academic Press, New York San Francisco London, pp 1836–1839
Eggstein M, Kulhmann E (1974) Triglycérides and glycerol determination after alkaline hydrolysis. In: Bergmeyer HU (ed) Methods of enzymatic analysis, Vol 4. Academic Press, London, pp 1825–1831
Luyckx AS (1972) Immunoassays for glucagon. In: Lefèbvre PJ, Unger RH (eds) Glucagon, molecular physiology, clinical and therapeutic implications. Pergamon Press, Oxford, pp 285–298
Franchimont P (1966) Le dosage des hormones hypophysaires somatotropes et gonadotropes et son application clinique. Thesis. Arscia A.S., Brussels, N.Maloine S.A., Paris
Nakagawa S, Nakayama H, Sasaki T, Yoshimo K, Yu Y, Shimozaki K, Aoki S, Mashimo K (1973) Simple method for the determination of serum free insulin levels in insulin-treated patients. Diabetes 22: 590–600
Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548
Christiansen HA (1970) A new method for determination of insulin binding immunoglobulins in insulin-treated diabetic patients. Horm Metabol Res 2: 187–188
Schoos R, Schoos-Barbette S, Lambotte C (1978) Dosage of hemoglobin A1c by isoelectrofocusing. Clin Chim Acta 86: 61–65
del Pozo E, Neufeld M, Schlüter K, Tortosa F, Clarenbach P, Bieder E, Wendel L, Nüesch E, Marbash P, Cramer H, Kerp L (1986) Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 111: 433–439
Scheen AJ, Gillet J, Guiot J, Henrivaux P, Jandrain B, Lefèbvre PJ (1986) Attempt to prevent the dawn phenomenon by a bedtime subcutaneous injection of a somatostatin analogue (SMS 201-995) in Type-1 (insulin-dependent) diabetic patients. Diabetologia 29: 590–591 (Abstract)
Johnston DG, Davies RR, Turner SJ (1986) Effects of somatostatin and SMS 201-995 on carbohydrate metabolism in normal man. Scand J Gastroent 21 [Suppl 119]: 158–165
Davies RR, Miller M, Turner SJ, Goodship THJ, Cook DB, Watson M, McGill A, Ørskov H, Alberti KGMM, Johnston DG (1986) Effects of somatostatin analogue SMS 201-995 in normal man. Clin Endocrinol 24: 665–674
Serrano-Rios M, Navascues I, Saban J, Ordonez A, Sevilla F, del Pozo E (1986) Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. J Clin Endocrinol Metab 63: 1071–1074
MacGorman LR, Rizza RA, Gerich JE (1981) Physiological concentrations of growth hormone exert insulin-like and insulin antagonistic effects of both hepatic and extrahepatic tissues in man. J Clin Endocrinol Metab 53: 556–559
Gerich JE, Lorenzi M, Bier DM, Tsalikian E, Schneider V, Karam JH, Forsham PH (1976) Effects of physiological levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. J Clin Invest 57: 875–884
Johansson C, Wisen O, Efendic J, Uvnas-Wallensten K (1981) Effects of somatostatin on gastrointestinal propagation and absorption of oral glucose in man. Digestion 22: 126–137
Williams G, Fuessl H, Kraenzlin M, Bloom SR (1986) Postprandial effects of SMS 201-995 on gut hormones and glucose tolerance. Scand J Gastroent 21 [Suppl 119]: 73–83
Rosak C, Althoff PH, Fassbinder W, del Pozo E, Boehm BO (1986) Veränderungen der hormoneilen Gegenregulation nach insulininduzierter Hypoglykämie bei gleichzeitiger Gabe des Somatostatinanalogons SMS 201-995. Med Klin 81: 773–778
McGarry JD, Foster DW (1980) Regulation of hepatic fatty acid oxidation and ketone body production. Ann Rev Biochem 49: 395–420
Schade DS, Eaton RP, Peake GT (1978) The regulation of plasma ketone body concentration by counterregulatory hormones in man. II. Effect of growth hormone in diabetic man. Diabetes 27: 916–924
Scheen AJ, Henrivaux P, Jandrain B, Lefèbvre PJ (1987) U-100 insulin gives some protection against metabolic deterioration during CSII interruption. Diabetes Care 10: 707–711
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scheen, A.J., Gillet, J., Rosenthaler, J. et al. Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in Type 1 (insulin-dependent) diabetic patients. Diabetologia 32, 801–809 (1989). https://doi.org/10.1007/BF00264911
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00264911